文献速递甲状腺与颈部外科

甲状腺腺叶切除术后15年随访:近半数需长期激素替代

Thyroid hormone replacement following lobectomy: Long-term institutional analysis 15 years after surgery.
PubMed 文献 · Surgery · 2022-10-04

该研究回顾性分析了2005年1月至2010年7月期间接受甲状腺腺叶切除术的235例患者,中位随访7.2年,评估长期甲状腺激素替代治疗需求。结果显示46.8%的患者术后需要激素替代,其中24%在术后2年及以上才开始治疗;多因素分析仅桥本甲状腺炎与激素替代独立相关。结论建议腺叶切除术后应充分告知患者并至少随访甲状腺功能2年。

要点

  • 腺叶切除术后长期甲状腺激素替代率为46.8%,近四分之一在术后2年后才启动。
  • 桥本甲状腺炎是术后需激素替代的独立预测因素(OR 2.88,95%CI 1.3-6.6)。
  • 术后应至少监测甲状腺功能2年,以便及时发现并启动替代治疗。

核心结论

  • 长期随访下,因良性病变行腺叶切除术的患者近50%需要甲状腺激素替代治疗,且近四分之一在术后2年及以上才开始治疗。

研究设计与样本

  • 单中心回顾性队列研究,纳入2005年1月至2010年7月接受甲状腺腺叶切除术的患者235例,中位随访7.2年。

主要发现

  • 术后甲状腺激素替代治疗率为46.8%(110/235)。
  • 替代治疗组平均术后TSH为9.08±0.96 mIU/L,启动替代治疗的中位时间为621天,24%在术后≥2年才开始。
  • 桥本甲状腺炎在替代治疗组占21.8%,未替代组占8.0%(OR 3.2;95%CI 1.43-6.79;P < .001)。
  • 多因素分析仅桥本甲状腺炎与激素替代独立相关(OR 2.88;95%CI 1.3-6.6;P = .012)。
  • 年龄、性别及恶性肿瘤状态在替代治疗组与未替代组间无差异。

关键数值与推荐

  • 术后甲状腺激素替代治疗率46.8%(110/235)。
  • 桥本甲状腺炎患者接受替代治疗的OR为3.2(95%CI 1.43-6.79;P < .001),多因素OR为2.88(95%CI 1.3-6.6;P = .012)。
  • 替代治疗启动中位时间621天,24%在术后≥2年启动。

临床怎么用

  • 腺叶切除术前应告知患者术后近半数可能需长期甲状腺激素替代。
  • 术后至少监测甲状腺功能2年,以便及时发现延迟启动替代治疗的患者。
  • 对合并桥本甲状腺炎的患者应加强术后甲状腺功能监测。

局限性

  • 单中心回顾性研究,样本量235例,可能存在选择偏倚。
  • 随访时间中位7.2年,但部分患者可能失访或数据不完整。
  • 未报告替代治疗的具体指征及TSH启动阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The decision to pursue lobectomy versus total thyroidectomy is highly individualized. The rate of thyroid hormone replacement therapy after lobectomy varies considerably (15%-48%) and studies are limited by short-term follow-up. We sought to assess long-term thyroid hormone replacement therapy-requirement for lobectomy. METHODS: Patients undergoing lobectomy from January 2005 to July 2010 at an academic institution were reviewed. Demographic, laboratory, pathology, and thyroid hormone replacement therapy use were compared. RESULTS: In total, 235 patients were included. The rate of thyroid hormone replacement therapy after lobectomy was 46.8% (110/235). The majority were female (84.7%), with a mean age of 52 ± 1 years, 97% with benign pathology, and the median duration of follow-up was 7.2 years. Among the 110 thyroid hormone replacement therapy, the mean postoperative thyroid stimulating hormone level 9.08 ± 0.96m IU/L and the time to thyroid hormone replacement therapy-initiation was 621 days; 24% started therapy ≥2 years after surgery. There was no difference in age, sex, or malignancy. Hashimoto thyroiditis was diagnosed in 21.8% patients who underwent thyroid hormone replacement therapy versus 8.0% of those without thyroid hormone replacement therapy (odds ratio 3.2; 95% confidence interval, 1.43-6.79; P < .001). On multivariate analysis, only Hashimoto thyroiditis was independently associated with thyroid hormone replacement therapy use (odds ratio 2.88; 95% confidence interval, 1.3-6.6; P = .012). CONCLUSION: With long-term follow-up, nearly 50% of patients who underwent lobectomy for benign disease required thyroid hormone replacement therapy and nearly one-quarter of these patients not starting until ≥2 years after surgery. Therefore, patients who undergo thyroid lobectomy should be counseled appropriately and thyroid function followed for a minimum of 2 years.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Barranco H, Fazendin J, Lindeman B, et al. Thyroid hormone replacement following lobectomy: Long-term institutional analysis 15 years after surgery. Surgery. 2022. PMID: 36202649. doi:10.1016/j.surg.2022.05.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。